␣2 adrenergic receptor (␣2-AR) agonists have been used as antihypertensive agents, in the management of drug withdrawal, and as sedative analgesics. Since ␣2-AR agonists also influence the regulation of body temperature, we explored their potential as antipyretic agents. This study delineates the central neural substrate for the inhibition of rat brown adipose tissue (BAT) and shivering thermogenesis by ␣2-AR agonists. Nanoinjection of the ␣2-AR agonist clonidine (1.2 nmol) into the rostral raphe pallidus area (rRPa) inhibited BAT sympathetic nerve activity (SNA) and BAT thermogenesis. Subsequent nanoinjection of the ␣2-AR antagonist idazoxan (6 nmol) into the rRPa reversed the clonidine-evoked inhibition of BAT SNA and BAT thermogenesis. Systemic administration of the ␣2-AR agonists dexmedetomidine (25 g/kg, i.v.) and clonidine (100 g/kg, i.v.) inhibited shivering EMGs, BAT SNA, and BAT thermogenesis, effects that were reversed by nanoinjection of idazoxan (6 nmol) into the rRPa. Dexmedetomidine (100 g/kg, i.p.) prevented and reversed lipopolysaccharide-evoked (10 g/kg, i.p.) thermogenesis in free-behaving rats. Cholera toxin subunit b retrograde tracing from rRPa and pseudorabies virus transynaptic retrograde tracing from BAT combined with immunohistochemistry for catecholaminergic biosynthetic enzymes revealed the ventrolateral medulla as the source of catecholaminergic input to the rRPa and demonstrated that these catecholaminergic neurons are synaptically connected to BAT. Photostimulation of ventrolateral medulla neurons expressing the PRSx8-ChR2-mCherry lentiviral vector inhibited BAT SNA via activation of ␣2-ARs in the rRPa. These results indicate a potent inhibition of BAT and shivering thermogenesis by ␣2-AR activation in the rRPa, and suggest a therapeutic potential of ␣2-AR agonists for reducing potentially lethal elevations in body temperature during excessive fever.
Introduction
Regulating body temperature in the face of challenges from the environment and from disease processes is one of the most fundamental homeostatic functions of the CNS. Thermoregulatory circuits in the CNS orchestrate fever, an elevated core body temperature (T CORE ) that optimizes host immune responses to infection or inflammation. However, the irreversible protein denaturation ensuing from excessive and sustained elevations in T CORE (hyperpyrexia, "lethal fever") produces significant cell damage, compromising tissue function and contributing to the high mortality from a variety of rapidly fatal diseases, infections, and brain injuries, including cerebral malaria, meningitis, encephalitis, toxemia, HIV/AIDS, the abuse of amphetamine-based drugs, stroke, and intracranial hemorrhage and traumatic brain injury. Because an enhanced level of metabolic heat production (thermogenesis) in brown adipose tissue (BAT) and skeletal muscle (i.e., shivering) contribute significantly to the elevated T CORE in hyperpyrexia, a rapid and sustained inhibition of centrally driven thermogenesis would improve the prognosis and limit brain and tissue damage. However, few effective approaches exist for the rapid reversal of the extreme elevations in T CORE that are resistant to standard pharmacological antipyretic therapies based on cyclooxygenase inhibition. In particular, the effectiveness of attempts to decrease T CORE by mechanical cooling is limited by the reflex activation of thermogenic and heat conservation mechanisms that combat falls in T CORE . Thus, such mechanical approaches to decreasing T CORE during hyperpyrexia would benefit from an adjunctive therapy to block the physiological responses to external cooling.
The centrally generated elevation in T CORE during fever arises as a consequence of increased thermogenesis and reduced heat loss to the environment (Saper and Breder, 1994) , the same combination of thermal effector responses stimulated by central thermoregulatory networks to defend T CORE during a cold challenge (Morrison, 2011) . The premotor neurons controlling thermogenic effector activation are primarily within the region of the medullary rostral raphe pallidus area (rRPa) (Morrison et al., 2012) and project to the spinal cord to excite the BAT sympathetic preganglionic neurons and the ␣-motoneurons contributing to skeletal muscle shivering. Neurons in the ventrolateral medulla (VLM) provide a major inhibitory regulation of the sym-pathetic outflow to BAT, capable of reversing the increases in BAT heat production elicited during the febrile response (Cao et al., 2010) . Catecholaminergic neurons within the VLM project to the RPa (Card et al., 2006) , and spinally projecting neurons in the rRPa express ␣2 adrenergic receptors (␣2-ARs) (Guyenet et al., 1994) . Thus, the current studies tested the hypothesis that centrally acting ␣2-AR agonists clonidine and dexmedetomidine will block the activation of thermogenic premotor neurons in the rRPa, and thus could be effective antipyretic agents. We also identified the endogenous adrenergic input to the rRPa and demonstrated its capacity to inhibit thermogenesis via activation of ␣2-ARs in rRPa. These translational discoveries have wide therapeutic potential for reducing potentially lethal, centrally generated elevations in T CORE , and for the induction of therapeutic hypothermia. Identifying the precise site(s) and mechanism(s) of action of ␣2-AR agonists to reverse febrile thermogenesis could also contribute to the improved design of such pharmacologic agents by reducing off-target effects.
Materials and Methods
All procedures conform to the regulations detailed in the Guide for the Care and Use of Laboratory Animals (National Research Council, eighth edition) and were approved by the Animal Care and Use Committees of the Oregon Health and Science University or the University of Pittsburgh.
Acute physiology experiments in anesthetized rats
Male Sprague Dawley or Wistar rats (300 -450 g; Charles River Laboratories) were anesthetized with isoflurane (2-3% in 100% O 2 ) and the femoral artery and vein were cannulated. Rats were transitioned from isoflurane to urethane (750 mg/kg, i.v.) and ␣-chloralose (60 mg/kg, i.v.) anesthesia, except for those rats prepared for shivering EMG recordings, which were transitioned to Inactin (50 mg ⅐ kg Ϫ1 initial dose, 20 mg ⅐ kg Ϫ1 ⅐ h Ϫ1 continuous infusion thereafter; Sigma) anesthesia. In all rats, except those that were prepared for shivering EMG recordings, the trachea was cannulated, and the animal was artificially ventilated with 100% O 2 (stroke volume, 0.75-1 ml/100 g body weight, 50 -70 strokes per minute) and paralyzed with D-tubocurarine (0.6 mg/rat, i.v., supplemented thereafter with 0.3 mg when spontaneous respiratory activity was observed). Animals were placed in a stereotaxic frame with the incisor bar positioned 4 mm below the interaural line. A thermocouple inserted in the rectum was used to measure T CORE , which was maintained at 37.0 Ϯ 0.5°C with a heat lamp and a water-perfused thermal blanket, unless noted otherwise. BAT temperature (T BAT ) was recorded using a thermocouple placed in the interscapular BAT. Skin temperature (T SKIN ) was recorded using a thermocouple placed on the hindquarter skin.
BAT SNA and thermogenesis. A sympathetic nerve innervating the right interscapular BAT pad was recorded using bipolar hook electrodes as described previously (Madden and Morrison, 2009) . Nerve activity was differentially amplified (10,000 to 50,000 times; CyberAmp 380; Molecular Devices), filtered (1-300 Hz), digitized, and recorded onto a hard drive using Spike2 software (Cambridge Electronic Design). A continuous (4 s bins) measure of BAT SNA amplitude was calculated (Spike2 software) from the autospectra of sequential 4 s segments of BAT SNA as the root mean square value (square root of the total power in the 0.1 to 20 Hz band of the BAT SNA). The control level of BAT SNA was taken as the mean BAT SNA amplitude during a 2 min period of minimum BAT SNA recorded when the rat was in a warm condition (T CORE , Ͼ37°C) and basal BAT SNA was absent.
Shivering EMG recordings. Briefly, for EMG recording, bipolar pin electrodes (ϳ3 mm separation between poles) were inserted into nuchal, gastrocnemius, and masseter muscles, and the signal was filtered (100 -5000 Hz) and amplified (2000ϫ) with a CyberAmp 380 (Molecular Devices). As described previously (Nakamura and Morrison, 2011) , EMG amplitude was quantified (Spike2; Cambridge Electronic Design) in sequential 4 s bins as the square root of the total power (root mean square) in the 0 -500 Hz band of the autospectra of each 4 s segment of EMG.
Experimental protocols
The ␣2-AR agonist clonidine (1.2 nmol in 60 nl) was nanoinjected into the rRPa (3 mm caudal to lambda, on the midline, 9.6 to 9.8 mm ventral to dura over the cerebellum) to evaluate whether activation of ␣2-ARs in the rRPa inhibits BAT SNA and BAT thermogenesis evoked by (1) nanoinjection of prostaglandin E 2 (PGE 2 ; 60 ng in 60 nl saline; n ϭ 4) into the medial preoptic area (MPA; 0.2 mm caudal to bregma, 0.6 -0.8 mm lateral to bregma, 8.0 mm ventral to dura), or (2) cooling of the rat with a water-perfused thermal blanket (n ϭ 8). The clonidine nanoinjection into the rRPa was followed by a nanoinjection of the ␣2-AR antagonist, idazoxan (6 nmol in 120 nl) or saline vehicle (120nl) into the same rRPa site. Injection sites were verified by localization of fluorescent polystyrene microspheres (FluoSpheres F8797, F8801, or F8803; Invitrogen) included in the injectate (dilution, 1:200) .
To establish that systemically administered ␣2-AR agonists can inhibit febrile thermogenesis via activation of ␣2-ARs in the rRPa, rats (n ϭ 6) were prepared for recordings of BAT SNA and BAT thermogenesis and received a nanoinjection of PGE 2 (60 ng in 60 nl saline) into the MPA. A systemic injection of clonidine (100 g/kg, i.v.) was followed by a nanoinjection of idazoxan (6 nmol in 120 nl) into the rRPa. A separate group of rats (n ϭ 6) was prepared for recording shivering EMGs and received a nanoinjection of PGE 2 (60 ng in 60 nl saline) into the MPA followed by a systemic injection of dexmedetomidine (25 g/kg, i.v.) and a subsequent nanoinjection of idazoxan (6 nmol in 120 nl) into the rRPa.
Optogenetic experiments. Male Sprague Dawley rats (n ϭ 6; 350 -400 g; Charles River Laboratories) were anesthetized with isoflurane (2-3% in 100% O 2 ) and placed in a stereotaxic frame (incisor bar positioned at Ϫ11 mm from interaural zero). Following removal of a portion of the occipital bone, two nanoinjections (200 nl per injection of 3 ϫ 10 8 lentiviral particles per ml) of a lentiviral vector consisting of eight tandem repeats of the Phox2-binding site and an enhanced version of the photoactivatable cationic channel rhodopsin receptor 2 (H134R) fused to mCherry (PRSx8-ChR2-mCherry) (Abbott et al., 2009) were made into the VLM (0.8 and 1.2 mm rostral, 1.7 mm lateral, and 2.6 mm ventral to calamus scriptorius). After a 14 -34 d recovery period to allow for sufficient expression of the lentiviral vector, rats were prepared for BAT SNA recording as in the acute physiology protocol above. The photostimulation sites in the VLM targeted the approximate center of the region of the VLM that we demonstrated previously to inhibit BAT SNA (Cao et al., 2010) . Briefly, a fiber optic cable (200 m diameter; Thorlabs) was stereotaxically positioned in the VLM (1.0 -1.5 mm rostral, Ϯ1.7 mm lateral, and 2.3-2.5 mm ventral to calamus scriptorius). A diodepumped 473 nm laser (model CL-473-075-O; CrystaLaser) was used as the light source. The continuous output of the laser was set at 10 mW by direct light meter (Thorlabs) measurement of the power ouput at the end of the fiber optic cable. Photostimulation of the VLM consisted of 60 s trains of 10 ms light pluses delivered at 5, 10, 20, or 40 Hz. Photostimulation was performed before and after nanoinjection of idazoxan (6 nmol in120 nl) into the rRPa (on the midline, 2.8 -3 mm rostral, and 2.8 mm ventral to calamus scriptorius). Rats were then perfused transcardially with saline followed by 4% paraformaldehyde; brains were postfixed for 2-12 h in 4% paraformaldehyde and transferred to a 30% sucrose solution at 4°C for at least 1 d, at which time they were cut on a microtome (35 m, 1:6 series); and sections were preserved in cryoprotectant at Ϫ20°C until processed for immunohistochemistry.
Physiology experiments in free-behaving rats. Rats were implanted with a temperature transponder (IPTT-300; Bio Medic Data Systems) into the interscapular BAT. During a 1 week recovery period, rats received daily intraperitoneal injections of 0.5 ml sterile saline and were also acclimated for 2 h/d to an environmental chamber maintained at 24°C. On the experimental day, rats received an injection of either sterile saline (0.5 ml, i.p.; n ϭ 5) or dexmedetomidine (100 g/kg, i.p.; n ϭ 4) and, within 5 min, an injection of lipopolysaccaride (LPS; 10 g/kg/ml, i.p.). Rats were then placed in the environmental chamber maintained at 24°C. T BAT was assessed before and every 30 min for 3 h following the initial injection. In a separate group, rats received an injection of LPS (10 g/kg/ml, i.p.) followed 1.5 h later by an injection of either sterile saline (0.5 ml, i.p.; n ϭ 4) or dexmedetomidine (100 g/kg, i.p.; n ϭ 5). T BAT was assessed every 30 min for 3.5 h beginning just before the injection of LPS.
Anatomy experiments
Cholera toxin subunit b injections and immunohistochemical procedures. Standard stereotaxic and immunohistochemical procedures were used as described previously (Madden, 2012) . Briefly, male Sprague Dawley rats (n ϭ 4, 350 -400 g, Charles River Laboratories) were anesthetized with isoflurane (2-3% in 100% O 2 ) and placed in a stereotaxic frame (incisor bar positioned at Ϫ4 mm from interaural zero). Via a burr hole in the interparietal bone, cholera toxin subunit b (CTb) conjugated to Alexa Fluor 488 or Alexa Fluor 594 (100 -200 nl of 1 mg/ml; Invitrogen) was nanoinjected into the rRPa (3 mm caudal to lambda, on midline, 9.8 mm ventral to dura). One week later, rats were deeply anesthetized (100 mg/kg pentobarbital, i.p.) and perfused transcardially with saline fol- Figure 1 . Effect of activation of ␣2-ARs in the rRPa on BAT thermogenesis evoked by PGE 2 or cooling. A, C, The stimulation of BAT SNA evoked by nanoinjection of PGE 2 into the medial preoptic area (A) or cooling (C) was reversed by nanoinjection of the ␣2-AR agonist clonidine into the rRPa. Subsequent nanoinjection of the ␣2-AR antagonist idazoxan into the rRPa restored the PGE 2 -evoked (A) or cooling-evoked (C) BAT SNA, whereas nanoinjection of saline failed to reverse the effect of clonidine. Changes in T BAT , expired CO 2 , and HR paralleled those in BAT SNA. However, due to the short time period between injections, the thermogenic increase in T CORE and the thermal inertia of the BAT, T BAT , remained significantly elevated following nanoinjection of clonidine. A, D, Insets, Diagrams of anatomical drawings depict the locations of the centers of the nanoinjection sites. 3V, Third ventricle; ac, anterior commissure; OX, optic chiasm; LPO, lateral preoptic area; py, pyramidal tract. B, The means Ϯ SEM (n ϭ 4) of the time courses of the physiological variable (each point is a 30 s average of the variable value) for the PGE 2 -evoked responses are shown. *p Ͻ 0.05 (significant increases compared with the basal value before PGE 2 administration); # p Ͻ 0.05 (compared with the peak PGE 2 -evoked value just before clonidine administration). D, Means Ϯ SEM of the peak BAT SNA during cooling, the nadir within 10 min of nanoinjection of clonidine into the rRPa, and the peak within 10 min of subsequent injection of idazoxan (n ϭ 4) or saline into the rRPa (n ϭ 4). *p Ͻ 0.05 (compared with cooling evoked peak); # p Ͻ 0.05 (compared with clonidine-evoked nadir).
lowed by 4% paraformaldehyde; brains were removed, postfixed, saturated in a 30% sucrose solution, and cut on a microtome (35 m, 1:6 series); and sections were preserved in cryoprotectant at Ϫ20°C until processed for immunohistochemistry as follows. Sections were incubated in the primary antibody solution, goat anti-CTb (1:20,000 in antibody dilution solution; List Biological Laboratories, lot #7032A6) and mouse anti-tyrosine hydroxylase (TH; 1:1500; ImmunoStar) or mouse anti-dopamine ␤ hydroxylase (D␤H; 1:500; Millipore), for 16 h on a shaker table at room temperature. The tissue was incubated in the secondary antibody solution (donkey anti-mouse-Alexa 488, used at 1:200, A21206, Invitrogen; donkey anti-goat-Alexa 594, used at 1:200, A11058, Invitrogen) for 1 h. The tissue was rinsed in PBS, mounted on slides, and coverslipped using Prolong Gold anti-fade reagent (Invitrogen). Viral injections and immunohistochemical procedures. Adult male Sprague Dawley rats (275-350 g; Zivic-Miller Laboratories) were maintained on a 12 h light/dark cycle with ad libitum access to food and water. Rats were housed in a biosafety level 2 facility throughout the experiments. Rats were anesthetized with an intraperitoneal injection of ketamine (60 mg/kg) and xylazine (7 mg/kg). The interscapular BAT was exposed, and 0.1 l of an attenuated strain of pseudorabies virus [PRVBartha; 4 ϫ 10 8 plaque-forming units (pfu)/ml] was injected into five different sites (total volume, 0.5 l) using a 1 l Hamilton syringe. After injections, the skin was closed with wound clips. Different postinoculation times were used to estimate the temporal progression of the virus through the CNS after injection into BAT: 72-98 h. After the appropriate postinoculation time, rats were deeply anesthetized with ketamine (120 mg/kg) and xylazine (14 mg/kg) and perfused transcardially with 0.9% saline followed by paraformaldehyde lysine-periodate fixative. The brains were fixed for 3 h and preserved in 20% sucrose at 4°C. Serial coronal sections (35 m) were cut with a freezing-stage microtome, collected sequentially in eight sets, and stored in cryoprotectant solution at Ϫ20°C before immunohistochemical processing. A dual fluorescence labeling procedure was used to characterize neurons immunoreactive for PRV and D␤H or TH. This procedure was similar to our immunohistochemical protocol described previously (Tupone et al., 2011) except that the primary antibodies used in the current study were mouse monoclonal anti-TH (1:2000; Millipore), mouse monoclonal anti-D␤H (1:3000; Millipore Bioscience Research Reagents), and a rabbit polyclonal antiserum generated against acetone-inactivated virus (Rb133; 1:2000, kindly supplied by L. Enquist, Princeton University, Princeton, NJ). The secondary antibodies used were Cy3-conjugated donkey anti-rabbit IgG (1:500, red fluorescence to label PRV-infected neurons) and Cy2-conjugated donkey anti-mouse IgG (1:300, green fluorescence to label D␤H-containing neurons; both secondary antibodies were from Jackson ImmunoResearch Laboratories). For the longest postinoculation time (98 h; Fig. 5D ), to optimize the fluorescence in neurons with robust expression of PRV, fluorescence was reversed, and the secondary antibodies used were Alexa 488 anti-rabbit IgG (1:500, green fluorescence to Figure 2 . Effect of systemic administration of an ␣2-AR agonist and subsequent blockade of ␣2-ARs specifically in the the rRPa on BAT thermogenesis evoked by PGE 2 . A, Nanoinjection of PGE 2 into the MPA increased BAT SNA, T BAT , expired CO 2 , mean arterial pressure (MAP), and HR. Subsequent intravenous administration of clonidine reversed the increases in BAT SNA, T BAT , expired CO 2 , and HR, whereas MAP was increased further. Nanoinjection of the ␣2-AR antagonist idazoxan into rRPa restored the PGE 2 -evoked BAT SNA, T BAT , expired CO 2 , and HR. Inset, Diagrams of anatomical drawings depict the locations of the centers of the nanoinjection sites. 3V, Third ventricle; ac, anterior commissure; LPO, lateral preoptic area; OX, optic chiasm; py, pyramidal tract. B, Means Ϯ SEM (n ϭ 6) of the time courses of the physiological variables (each point is a 30 s average of the variable value). *p Ͻ 0.05 (significant increases compared with the basal value before PGE 2 administration or cooling); # p Ͻ 0.05 (compared with the peak PGE 2 -or cooling-evoked value just before clonidine administration).
label PRV-infected neurons) and Alexa 594 anti-mouse IgG (1:500, to label TH-containing neurons; both antibodies were from Invitrogen). Double-labeled, PRV-infected, TH-immunoreactive (TH-ir), or D␤H-ir neurons displayed yellow fluorescence. Tissue analysis. The neuroanatomical locations of PRV-infected neurons and TH-ir neurons in the VLM were based on a rat brain atlas (Paxinos and Watson, 2007) . PRV-infected neurons (non-TH-ir) and PRV-infected, D␤H-ir neurons (dual-labeled neurons) were counted in the VLM in consecutive sections from a 1:8 set of sections (245 m distance between consecutive sections). To account for the inherent variability in the viral infection of adipose tissue (Cano et al., 2003) , cases were grouped based on the total number of PRV-infected neurons in the VLM (intermediate infection, 145-200 neurons infected; late infection, 500 -700 neurons infected), and the mean Ϯ SEM was calculated for each group. Photomicrographs of PRV-infected neurons and D␤H-ir neurons and fibers were obtained using an image capture system (Simple PCI, version 6.6; Hamamatsu) attached to an Olympus BX51 fluorescence microscope. The photomicrographs were assembled into a plate using Adobe Photoshop to adjust contrast and brightness without altering the original colors.
Data and statistical analyses
BAT SNA, T BAT , T CORE , T SKIN , expired CO 2 , arterial pressure, and stimulus trigger pulses were digitized (Micro3 1401; Cambridge Electronic Design) and recorded onto a computer hard drive for analysis (Spike2; Cambridge Electronic Design).
All statistics were performed using Systat software (version 10; Cranes Software International). Data are expressed as mean Ϯ SEM. For each variable, statistical comparisons were done between the 30 s period before treatment and the 30 s window at the peak or nadir of the treatmentevoked effect. Statistical significance was assessed using a two-sample t test, or an ANOVA with repeated measures and post hoc testing as appropriate. Results with p Ͻ 0.05 were considered significant.
Results

␣2-AR activation in the rRPa reverses nonshivering thermogenesis
We tested the hypothesis that ␣2-AR activation in the rRPa would inhibit the increases in BAT SNA, BAT thermogenesis, and heart rate (HR) evoked during the febrile response to injection of PGE 2 into the MPA. As illustrated in Figure 1 , A and B, nanoinjection of PGE 2 (60 pmol) into the MPA increased BAT SNA, T BAT , expired CO 2 , MAP, and HR. Subsequent nanoinjection of the ␣2-AR agonist clonidine (1.2 nmol) into the rRPa promptly reversed the PGE 2 -evoked increase in BAT SNA (t (3) ϭ 2.458, p ϭ 0.046, compared to PGE 2 -evoked peak), resulting in reductions Figure 3 . Effect of systemic administration of an ␣2-AR agonist and subsequent blockade of ␣2-ARs specifically in the rRPa on shivering thermogenesis evoked by PGE 2 . A, Nanoinjection of PGE 2 into the MPA increased shivering EMG activity in the nuchal, gastrocnemius, and masseter muscles and increased T CORE . Subsequent intravenous injection of dexmedetomidine (DEX) completely inhibited all EMG activity and decreased T CORE. Nanoinjection of the ␣2-AR antagonist idazoxan into the rRPa reversed the DEX-induced inhibition of shivering EMG activity in all recorded muscles. Inset, Diagrams of anatomical drawings depict the locations of the centers of the nanoinjection sites. ac, Anterior commissure; LPO, lateral preoptic area; OX, optic chiasm; py, pyramidal tract. B, Means Ϯ SEM (n ϭ 6) of the time courses of the physiological variables (each point is a 30 s average of the variable value). *p Ͻ 0.05 (significant increases compared with the basal value before PGE 2 administration); # p Ͻ 0.05 (compared with the peak PGE 2 -evoked value just before DEX administration).
in the elevated levels of T BAT and expired CO 2 (an indirect indicator of metabolic O 2 consumption; t (3) ϭ 5.461, p ϭ 0.006). The clonidine-evoked effects were long lasting (in cases where saline or no subsequent treatment was administered, the sympathoinhibitory effect of clonidine persisted for Ͼ20 min). Nanoinjection of the ␣2-AR antagonist idazoxan (6 nmol) into the same rRPa site completely reversed the effects of clonidine (BAT SNA, t (3) ϭ Ϫ2.384, p ϭ 0.049; expired CO 2 , t (3) ϭ Ϫ4.825, p ϭ 0.008; Fig. 1 A, B) . Skin cooling also increased BAT SNA. The BAT SNA response to environmental cooling was inhibited by nanoinjection of clonidine (1.2 nmol) into rRPa (t (3) ϭ 7.628, p ϭ 0.005 and t (3) ϭ 2.417, p ϭ 0.047 for the groups receiving subsequent idazoxan and saline, respectively; Fig. 1C,D) . Subsequent nanoinjection of idazoxan (6 nmol) into the same rRPa site resulted in a small transient (ϳ2-3 min) decrease in residual BAT SNA followed by a complete reversal of the clonidineevoked sympathoinhibition (Fig. 1C,D ; t (3) ϭ Ϫ9.196, p ϭ 0.003, compared to clonidine-evoked nadir). Nanoinjection of saline into the rRPa failed to reverse the clonidine-evoked inhibition of BAT SNA ( Fig. 1D ; saline rRPa compared to cooling evoked, t (3) ϭ 2.512, p ϭ 0.043). Under warm conditions when BAT SNA was absent, injection of idazoxan alone did not increase BAT SNA (data not shown). 
Nanoinjection of idazoxan in rRPa reverses the inhibition of both nonshivering and shivering thermogenesis evoked by intravenous ␣2-AR agonists
To assess whether systemically administered ␣2-AR agonists can inhibit febrile BAT thermogenesis, we determined the effect of an intravenous injection of clonidine on BAT thermogenesis evoked by nanoinjection of PGE 2 in MPA (Fig. 2) . Nanoinjection of PGE 2 (60 pmol) into the MPA increased BAT SNA, T BAT , expired CO 2 , MAP, and HR (Fig. 2 A, B) . Subsequent injection of clonidine (25 g/kg, i.v.) promptly and completely reversed the increases in BAT SNA (t (5) ϭ 3.586, p ϭ 0.016), T BAT (t (5) ϭ 5.085, p ϭ 0.004), expired CO 2 (t (5) ϭ 4.392, p ϭ 0.007), and HR (t (5) ϭ 10.078, p Ͻ 0.001; Fig. 2 A, B) . Intravenous clonidine also significantly elevated MAP above the level attained following PGE 2 in MPA (t (5) ϭ Ϫ4.895, p ϭ 0.004). The increase in MAP is attributable to peripheral vascular effects of the bolus administration of ␣2-AR agonists (van Zwieten, 1980) and is avoided clinically by slowly infusing highly selective ␣2-AR agonists (Flower and Hellings, 2012; Lam et al., 2012) . To identify the site of action for the antipyretic effect of systemically administered ␣2-AR agonists, we determined whether nanoinjection of idazoxan in the rRPa would reverse the antipyretic effect of intravenous clonidine. Nanoinjection of idazoxan in rRPa reversed the decreases in BAT SNA (t (5) ϭ Ϫ4.192, p ϭ 0.009), T BAT (t (5) ϭ Ϫ5.315, p ϭ 0.003), CO 2 (t (5) ϭ Ϫ5.590, p ϭ 0.003), and HR (t (5) ϭ Ϫ10.786, p Ͻ 0.001) evoked by intravenous injection of clonidine ( Fig. 2A,B) .
To determine whether systemically administered ␣2-AR agonists also inhibit febrile shivering thermogenesis, dexmedetomi- dine (25 g/kg, i.v.) was injected during episodes of shivering evoked by nanoinjection of PGE 2 in MPA (Fig. 3) . Systemic administration of dexmedetomidine promptly and completely inhibited shivering EMGs recorded from the nuchal (t (4) ϭ 3.356, p ϭ 0.028), gastrocnemius (t (3) ϭ 3.242, p ϭ 0.048), and masseter (t (4) ϭ 10.983, p Ͻ 0.001) muscles and reversed the PGE 2 -evoked increase in T CORE (t (4) ϭ 2.236, p ϭ 0.045; Fig. 3 A, B) . The dexmedetomidine-induced inhibition of shivering was reversed by nanoinjection of idazoxan in the rRPa (nuchal, t (4) ϭ Ϫ2.415, p ϭ 0.037; gastrocnemius, t (3) ϭ Ϫ2.151, p ϭ 0.06; masseter, t (4) ϭ Ϫ10.058, p Ͻ 0.001; Fig. 3 A, B) .
Source of the catecholaminergic input to rRPa
There is a dense catecholaminergic innervation of the rRPa, as indicated by the many fibers and axonal swellings within this area that are immunoreactive for the catecholamine biosynthetic enzymes D␤H (Figs. 4 A, 5A ). To determine which catecholaminergic neurons innervate the rRPa and thereby provide potential endogenous sources of catecholamines to activate the thermogenesis inhibiting ␣2-ARs in this region, we injected the retrograde tracer CTb into the rRPa (Fig. 4 B, C) and assessed the presence of CTb in neurons that were immunoreactive for D␤H, TH, or phenylethanolamine N-methyltransferase (PNMT). The extent of the CTb injection sites encompassed the entire rRPa and also extended into the raphe magnus (RMg) as well as around the medial edges of the pyramidal tracts (Fig. 4 B, C) . Double-labeled, D␤H-ir, and CTb-ir neurons (Fig. 4D-G) were found in the VLM (Fig. 4H ) , extending caudally from ϳ0.5 mm caudal to the facial nucleus for ϳ2 mm, but concentrated in the region between 12.5 to 13.5 mm caudal to bregma (Paxinos and Watson, 2007) . This region corresponds largely to the caudal C1 cell population (Card et al., 2006; Schreihofer and Sved, 2011) , and indeed many CTblabeled neurons in the VLM were immunoreactive for PNMT (data not shown). Based on the difference in the number of D␤H-ir versus PNMT-ir neurons in the VLM, it is likely that some rostral A1 neurons were also retrogradely labeled from the rRPa. In addition, there were many CTb-labeled neurons in the VLM that were not immunoreactive for D␤H or TH (Fig. 4I ). There were also many CTb-labeled neurons in the rostral pons near the medial paralemniscal nucleus in close proximity to the A7 catecholaminergic cell population; however, none of these neurons were immunoreactive for either D␤H or TH (Fig. 4J-M ) . In addition, very few A2 neurons (fewer than five cells per rat) or A5 cells (fewer than five cells per rat) and no A6 cells contained CTb.
Catecholaminergic neurons in the VLM are synaptically connected to BAT
To define the anatomical locations of catecholaminergic neurons in the VLM that are synaptically connected to BAT, we injected PRV into BAT and assessed the presence of PRV in catecholaminergic neurons in the VLM at a series of postinoculation times following PRV injection. As reported previously (Cano et al., 2003) , neurons in the RPa are infected at early infection times, consistent with their infection arising from the direct spinal projection of the BAT sympathetic premotor neurons in rRPa (Morrison et al., 2012) . The PRV-infected neurons in the rRPa are found in a dense network of highly varicose D␤H-ir fibers (Fig. 5A) . A few D␤H-ir neurons in the rostral VLM (RVLM) are infected by PRV at early infection times. Many D␤H-ir neurons in the rostral VLM are infected by PRV at intermediate and late infection times (Figs. 5B, 6 A, B) . At later infection times (Fig.  5D ) double-labeled, PRV-ir, and D␤H-ir neurons appear more caudally in the region of the VLM between 12.5 and 13.5 mm caudal to bregma, corresponding to the area where D␤H-ir neurons are labeled following injection of CTb in rRPa (compare Figs. 4 H, 6B) . The timing of the PRV infection of these VLM neurons is consistent with their infection arising from their axonal projections to the RPa, or to other brain regions that are infected earlier. In addition to the D␤H-ir neurons in the VLM, there were many infected neurons in the VLM that were not D␤H-ir (Fig. 5B-D) . As with the CTb-labeled projection from the VLM to the rRPa, the noncatecholaminergic population of VLM neurons comprised the majority of PRV-labeled cells within this area and was intermingled with the D␤H-ir, PRVinfected population.
At intermediate infection times there were many A7 neurons labeled with PRV (Fig. 5E ), consistent with their infection arising from a direct spinal projection. At later infection times, some PRV-infected neurons lacking D␤H immunoreactivity appeared medial to the A7 neurons. At the caudal level of the A7 cell population, there were PRV-infected neurons lacking D␤H immunoreactivity lateral to the A7 cell population (Fig. 5F ) in an area where noncatecholaminergic, CTb-labeled neurons were observed following injection of CTb in rRPa (compare Figs. 4M, 5F ).
Optogenetic activation of VLM neurons inhibits BAT thermogenesis
To determine whether activation of catecholaminergic neurons in the VLM inhibits BAT SNA and BAT thermogenesis via activation of ␣2-ARs in the rRPa, we used an optogenetic approach to preferentially activate catecholaminergic neurons within the VLM, and we determined whether blockade of ␣2-ARs in the rRPa would prevent the photostimulation-evoked inhibition of BAT SNA and BAT thermogenesis. Injection of the PRSx8-ChR2-mCherry lentivirus into the VLM produced mCherry expression in neurons (Fig. 7B) , most of which (53 Ϯ 7%; n ϭ 6) were immunoreactive for D␤H (Fig. 7C) . PRSx8-ChR2-mCherry expression was robust and, in addition to expression in the cell soma, was found in fibers and terminals of infected neurons, with an especially dense expression in fibers and axonal swellings in Figure 6 . A, B, Counts (mean Ϯ SEM) of PRV-only (white circles) and PRV-ir, D␤H-ir (black squares) neurons throughout the VLM (from 11 to 15 mm caudal to bregma) at intermediate (A; n ϭ 2) and late infection times (B; n ϭ 3). Note the progression of infection: at the intermediate infection time, very few catecholaminergic neurons are infected with PRV in the caudal VLM (ϳ12.75-13.5 mm caudal to bregma), whereas at the late infection time, many catecholaminergic neurons of this region begin to become infected with PRV. the rRPa (Fig. 7D) . Photostimulation of the right VLM (60 s; 5-40 Hz; 10 ms pulses; ϳ10 mW), the side containing ChR2-expressing neurons, abruptly inhibited cold-evoked BAT SNA and decreased T BAT in a frequency-dependent manner, with the 40 Hz stimulation completely inhibiting BAT SNA (Fig. 7 E, F ) . This BAT sympathoinhibition was attenuated by nanoinjection of idazoxan into the rRPa (two-way repeated measures ANOVA, drug effect, F (1,6) ϭ 12.497, p ϭ 0.012; frequency effect, F (3,18) ϭ 19.868, p Ͻ 0.001; no significant interaction effect, F (3,18) ϭ 2.329, p ϭ 0.114; Fig. 7G-I ) . The photostimulation-evoked decreases in T BAT were modest and did not differ significantly between the trials before and after nanoinjection of idazoxan (Fig. 7J ) , likely due to the short duration of photostimulation and the thermal inertia of BAT. Photostimulation of the left, uninfected VLM had no effect.
Intravenous injection of dexmedetomidine prevents/reverses LPS-evoked fever
To assess whether systemic administration of an ␣2-AR agonist was capable of preventing or reversing fever in a free-behaving rat, an intraperitoneal injection of dexmedetomidine or saline was given to rats either before or 1.5 h after an intraperitoneal injection of LPS. Following saline administration, an injection of LPS increased T BAT (Fig. 8 A) . The increase in T BAT evoked by LPS was prevented for Ͼ3 h by pretreatment with dexmedetomidine (two-way repeated measures ANOVA, drug effect, saline vs dexmedetomidine, F (1,7) ϭ 77.514, p Ͻ 0.001; time effect, F (6,42) ϭ 6.808, p Ͻ 0.001; interaction effect, F (6,42) ϭ 9.684, p Ͻ 0.001). In fact, T BAT decreased by nearly 3°C following pretreatment with dexmedetomidine (Fig. 8 A) . Similarly, when dexmedetomidine was injected 1.5 h after administration of LPS, the hyperthermia evoked by LPS was reversed, and indeed T BAT decreased by ϳ2.5°C (falling ϳ2.0°C below the basal, pre-LPS temperature; Fig. 8 B; two-way repeated measures ANOVA, drug effect, saline vs dexmedetomidine, F (1,7) ϭ 20.372, p ϭ 0.003; time effect, F (7,49) ϭ 11.434, p Ͻ 0.001; interaction effect, F (7, 49) ϭ 15.824, p Ͻ 0.001).
Discussion
In the present study, we demonstrate that systemic administration of ␣2-AR agonists reverses LPS-and central PGE 2 -evoked fevers and can induce a modest hypothermia in normal ambient temperatures. These effects arise from a potent inhibition of the metabolic heat production in BAT and in skeletal muscle during shivering due to an ␣2-AR-mediated inhibition of the populations of premotor neurons in the rRPa that are responsible for the descending excitatory drives to spinal BAT sympathetic preganglionic neurons and to spinal ␣-motoneurons. The catecholaminergic neurons providing the endogenous sources of adrenergic agonist for the ␣2-AR in the rRPa are located in the region of the caudal C1/rostral A1 catecholaminergic cell groups in the VLM. These findings explicate a novel mechanism for the inhibitory regulation of metabolic heat production and support a novel pharmacological approach to the control of excessive or neurogenic fevers that are resistant to commonly prescribed, cyclooxygenase inhibition-based antipyretic therapies.
␣2-AR agonists cause a modest hypothermia in the rodent (Millan et al., 2000; Lähdesmäki et al., 2003) , attenuate febrile responses in rabbits (Szreder, 1997) and horses (Kendall et al., 2010) , and reduce human shivering in clinical hypothermic settings (Weant et al., 2010; Logan et al., 2011) . Early studies to identify the site and mechanism underlying the hypothermic effects of ␣2-AR agonists focused on the thermoregulatory circuits in the preoptic area (Mallick and Alam, 1992; Quan et al., 1992; Romanovsky et al., 1993; Millan et al., 2000) . However, the results were inconclusive, with other studies reporting hyperthermia (Romanovsky et al., 1993; Feleder et al., 2004 Feleder et al., , 2007 or no change in body temperature (Osaka, 2009) following preoptic injection of an ␣2-AR agonist. Our demonstration that rRPa injection of an ␣2-AR antagonist reversed the inhibitions of BAT thermogenesis and shivering evoked by systemic administration of ␣2-AR agonists strongly supports the view that the hypothermic and antipyretic effects of ␣2-AR agonists are mediated by activation of ␣2-ARs in the rRPa. The localization of ␣2-ARs on spinally projecting neurons in the RPa (Guyenet et al., 1994) and the essential role played by spinally projecting premotor neurons in the rRPa in controlling thermoregulatory and febrile activations of BAT thermogenesis and shivering (Nakamura and Morrison, 2011; Morrison et al., 2012) are consistent with a model in which ␣2-AR agonists binding to inhibitory ␣2-ARs on thermogenic premotor neurons in rRPa reduces their responses to excitatory inputs, including those from the dorsomedial hypothalamus, which are essential for the activation of thermogenic premotor neurons in rRPa controlling metabolic heat production during cold exposure and fever (Madden and Morrison, 2004; Nakamura and Morrison, 2007, 2011) .
Potent inhibition of BAT SNA and BAT thermogenesis can be elicited by activation of neurons over an ϳ3 mm rostrocaudal extent of the VLM that extends from the facial nucleus to the obex Cao et al., 2010) . The present demonstrations that neurons in the caudal C1/rostral A1 region of the VLM provide the catecholaminergic input to the rRPa and that ␣2-AR activation in the rRPa inhibits BAT SNA and BAT thermogenesis suggest that activation of ␣2-ARs in the rRPa by catecholamines released from these VLM neurons contributes significantly to the potent inhibition of BAT SNA evoked from this region of the VLM. However, because idazoxan injections into the rRPa did not completely block the inhibition of BAT SNA evoked from the caudal C1/rostral A1 region of the VLM, a nonadrenergic input from the VLM to the rRPa could contribute, since retrograde tracing revealed a significant noncatecholaminergic input from the caudal C1/rostral A1 region of the VLM to the rRPa and catecholaminergic neurons in the VLM may release other neurotransmitters (Stornetta et al., 1999 (Stornetta et al., , 2002 Abbott et al., 2012) . VLM neurons may contribute to the inhibition of BAT SNA via an indirect pathway. In this regard, following lentivirus injection into the VLM, we observed PRSx8-ChR2-mCherry-expressing fibers in brain regions including the median preoptic area, paraventricular hypothalamus, and nucleus tractus solitarius, from which inhibitions of BAT SNA can also be elicited (Nakamura and Morrison, 2008; Madden and Morrison, 2009; Cao et al., 2010) .
Although catecholaminergic neurons in the caudal C1/rostral A1 region of the VLM (12.5 to 13.5 mm caudal to bregma) project strongly to the rRPa (Fig. 4H ) , we found very few C1 cells in the RVLM (ϳ11.75 to 12.25 mm caudal to bregma) that were retrogradely labeled from the rRPa. These results are consistent with the report that the rostral levels of RPa are devoid of EGFPexpressing axon terminals following virally mediated EGFP expression selectively in the rostral C1 catecholaminergic neurons of the RVLM (Card et al., 2006) . Thus, if the C1 cells in the RVLM participate in the inhibition of BAT thermogenesis elicited from this most rostral level of the VLM (Cao et al., 2010), we postulate that this effect would be indirect, rather than through a direct input to the rRPa.
Catecholaminergic neurons in the RVLM (i.e., rostral C1 neurons), as well as neurons in rRPa, are among the first brainstem PRV-ir neurons at early postinoculation times, reflecting their infection via their spinal projections and their roles as premotor neurons (Cano et al., 2003) . The dense network of highly varicose D␤H fibers surrounding the PRV-ir neurons in the rRPa is consistent with a direct catecholaminergic input to BAT sympathetic premotor neurons. The source of this catecholaminergic input to BAT-projecting neurons in rRPa is suggested by the PRV infection of TH-ir neurons in the caudal C1 region of the VLM at later postinoculation times, consistent with these neurons becoming infected via their projections to premotor regions, such as the rRPa, that were infected at the earlier postinoculation times. The localization of CTb retrograde labeling of catecholaminergic neurons in the caudal C1 region of the VLM following CTb injections in rRPa indicates that at least some of the PRV-ir and TH-ir neurons in the caudal C1 region of the VLM became infected specifically via their projection to BAT premotor neurons in the rRPa. Our findings with PRV transsynaptic retrograde tracing from BAT provide further support for the division of the VLM into regions that can inhibit BAT thermogenesis via distinct pathways, with only neurons in the caudal C1 region providing a direct catecholaminergic input to the rRPa. The functions of these distinct inhibitory pathways and the physiological stimuli through which they may be differentially activated remain to be determined.
Our observation that none of the rRPa-projecting neurons in the A7 region of the rostral pons contain D␤H or TH is inconsistent with a report that A7 noradrenergic neurons were retrogradely labeled following injection of CTb into the rostral medullary raphe (Yoshida et al., 2009 ). This discrepancy is most likely explained by differences in the CTb injection sites. Since the CTb injections in the study by Yoshida et al. (2009) were relatively large and not specifically targeted to the rRPa, with many injections including the RMg and pyramidal tract and some injections completely excluding the rRPa, the labeling of A7 neurons may be due to their projections into areas outside of rRPa. Since the current study specifically targeted the rRPa, our CTb injections were nearly completely confined to the rRPa.
Clonidine, dexmedetomidine, and idazoxan have affinities for both ␣2-ARs and imidazoline receptors (Ernsberger et al., 1987 (Ernsberger et al., , 1990 Savola and Savola, 1996) . Although systemic administration of a specific imidazoline receptor agonist decreases body temperature (Thorn et al., 2012) , it is unlikely that the inhibitions of thermogenesis observed in the current studies are mediated by activation of imidazoline receptors in the rRPa because (1) ␣2-ARs are expressed in spinally projecting neurons of the RPa (Guyenet et al., 1994) , (2) the hypothermic actions of ␣2-AR agonists are attenuated in mice lacking ␣2-ARs (Hunter et al., 1997), and (3) the imidazoline binding site has not been localized in the rRPa (Brüning et al., 1987; Ernsberger et al., 1995; Ruggiero et al., 1995) .
Potential physiological roles for the ␣2-AR-mediated inhibition of the metabolic heat production and energy consumption by BAT thermogenesis and shivering are suggested by the observations that catecholaminergic neurons of the VLM are activated by hypoxia (Hirooka et al., 1997) and by glucoprivation (Ritter et al., 1998) , two stimuli that inhibit BAT SNA and BAT thermogenesis (Madden and Morrison, 2005; Madden, 2012) . Additionally, a catecholaminergic inhibition of thermogenesis may contribute to the inability of D␤H knock-out mice to initiate torpor (Swoap and Weinshenker, 2008) . The physiological role(s) of BAT sympathoinhibitory mechanisms in the VLM and the role of ␣2-AR activation in the rRPa in specific physiological responses remain to be investigated.
In conclusion, ␣2-AR activation in the rRPa elicits a potent inhibition of both febrile-evoked and cold-evoked BAT thermogenesis and shivering. Neurons in the caudal C1 region of the VLM provide the endogenous catecholaminergic input activating ␣2-AR in the rRPa. These discoveries have wide and immediate therapeutic potential for reducing potentially lethal, centrally generated elevations in body temperature, and for complementing existing approaches to the effective and rapid induction of therapeutic hypothermia. Furthermore, by better defining the precise mechanisms of the thermolytic properties of ␣2-AR agonists, this study provides a foundation for the improved design of agents targeting these pathways.
